DOCSLIB.ORG

Quality Assessment Enzyme Analysis for Lysosomal Storage Diseases ERNDIM / EUGT Meeting 5-6 October 2006, Prague

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quality Assessment Enzyme Analysis for Lysosomal Storage Diseases ERNDIM / EUGT Meeting 5-6 October 2006, Prague QQuality Assessment Enzyme Analysis for Lysosomal Storage Diseases ERNDIM / EUGT meeting 5-6 October 2006, Prague Results of 1st “large scale” pilot Quality Assessment Enzyme Analysis for Lysosomal Storage Diseases Laboratories Rotterdam Hamburg/Heidelberg Dr, Zoltan Lukacs/Dr. Friederike Bürger QA-pilot for LSD’s the aims • Inter-laboratory variation ─ Many participants: > 30 • Intra-laboratory variation ─ Analyse two pairs of identical control samples (blind) • Proficiency testing of enzyme deficiencies ─ Which samples are best? - Blood samples: most widely used, but impractible - Fibroblasts: good but laborious - EBV lymphoblasts: easy to obtain, not widely used QA-pilot for LSD’s the set up • Samples, without clinical information ─ Leukocytes ─ EBV lymphoblasts ─ Fibroblasts • Enzymes: easy ones ─ 4MU-substrates ─ Simple colorimetric assays • Shipping: economic ─ Send at room temp., postal service - Lyophilised enzymes, stable at room temp. for 5 days - Fibroblasts • Data entry through existing ERNDIM programmes ─ “Metabolite presentation” (www.erndimqa.nl Æ Lysosomal Enzymes) QA-pilot for LSD’s the participants • Questionnaire to members (85 from 21 countries) ─ 40 labs want to join a QA-pilot ─ 65% want to include DBS in future QA-schemes • Samples sent, data returned ─ 40 labs received samples ─ 36 labs entered data on www.erndimqa.nl QA-pilot for LSD’s the samples • 10 samples ─ 4 leukocytes (two duplicate samples) ─ 4 EBV lymphoblasts ─ 2 fibroblasts • 10 easy enzymes ─ specific enzyme activity (e.g.. nmol/h/mg) ─ normalise to % of mean control • 2 separate experiments ─ test reproducibility QA-pilot for LSD’s Control fibroblasts, specific enzyme activity Å Deficient? QA-pilot for LSD’s Control fibroblasts, specific enzyme activity Range of 18 labs: 4 – 460 nmol/h/mg Å Deficient? QA-pilot for LSD’s Control fibroblasts, % of participants mean control Range of 18 labs: 40 – 127 % of Mean QA-pilot for LSD’s Gaucher fibroblasts, specific enzyme activity How do these values relate to the control range of the participant? QA-pilot for LSD’s Gaucher fibroblasts, specific enzyme activity SD scores (nmol/h/mg) not useful for enzyme deficiencies QA-pilot for LSD’s Gaucher fibroblasts, % of participants mean control >3SD: 4 or 400 % of Mean? Æ deficient or normal? QA-pilot for LSD’s Gaucher fibroblasts, % of participants mean control >3SD: 4 or 400 % of Mean? Æ deficient or normal? Range of 18 labs: 0.1 – 11 % of Mean SD scores (% mean control) with cut-off not useful for enzyme deficiencies Control leukocytes Specific enzyme activity (left) versus % of mean control (right) beta-Hexosaminidase A beta-Hexosaminidase (A+B) beta-Galactosidase β-Hexosaminidase A β-Hexosaminidase A+B β-Galactosidase 2000 200 8000 400 300 160 180 350 140 250 160 1500 6000 300 120 140 200 250 100 120 1000 100 4000 200 150 80 80 150 60 nmol / h / mg 100 60 500 2000 100 40 % of mean control 40 50 50 20 20 0 0 0 0 0 0 01234 01234 01234 Control leukocytes Specific enzyme activity (left) versus % of mean control (right) beta-Hexosaminidase A beta-Hexosaminidase (A+B) beta-Galactosidase β-Hexosaminidase A β-Hexosaminidase A+B β-Galactosidase 2000 200 8000 400 300 160 180 350 140 250 160 1500 6000 300 120 140 200 250 100 120 1000 100 4000 200 150 80 80 150 60 nmol / h / mg 100 60 500 2000 100 40 % of mean control 40 50 50 20 20 0 0 0 0 0 0 01234 01234 01234 Control leukocytes Specific enzyme activity (left) versus % of mean control (right) ASA 0 degrees ASA 37 Arylsulfatase A (0°) Arylsulfatase A (37°) 500 175 350 160 140 150 300 400 120 125 250 100 300 100 200 h / mg 17 80 75 150 200 nmol / h / mg 60 nmol / % of mean control of mean % 50 control of mean % 100 40 100 25 50 20 0 0 0 0 01234 01234 Control leukocytes Specific enzyme activity (left) versus % of mean control (right) ASA 0 degrees ASA 37 Arylsulfatase A (0°) Arylsulfatase A (37°) 500 175 350 160 140 150 300 400 120 125 250 100 300 100 200 h / mg 17 80 75 150 200 nmol / h / mg 60 nmol / % of mean control of mean % 50 control of mean % 100 40 100 25 50 20 right-data is missing 0 0 0 } 0 01234 01234 Control EBV lymphoblasts Specific enzyme activity (left) versus % of mean control (right) BHEX-A EBV BHEX-T EBV BGAL EBV β-Hexosaminidase A β-Hexosaminidase A+B β-Galactosidase 2500 250 6000 200 250 120 180 5000 100 2000 200 160 200 140 4000 80 1500 150 120 150 3000 100 60 1000 100 80 100 nmol / h / mg 2000 40 60 % of mean control of mean % 500 50 40 50 1000 20 20 0 0 0 0 0 0 01234 01234 01234 Control EBV lymphoblasts Specific enzyme activity (left) versus % of mean control (right) ASA 0 EBV ASA 37 EBV Arylsulfatase A (0°) Arylsulfatase A (37°) 350 250 120 160 140 300 100 200 120 250 80 100 150 200 h / mg 60 80 17 150 100 60 nmol / h / mg nmol / 40 % of mean control of mean % 100 control of mean % 40 50 20 50 20 0 0 0 0 01234 01234 EBV lymphoblasts are suitable for QA for enzyme analysis enzyme activity remaining (%) 100 25 50 75 0 Asp.g lucosaminidase Stability of20lysosomalenzymesin a-Iduronidase lyophilised leukocyte pellets(n=4) b-Glucosidase GlcNAc-6S sulfatase Arylsulfatase B 0, 1 or 3 weeks at room temperature 3weeks 1 or room at 0, a-Galactosidase a-NAc-g alactosaminidase a-Fucosidase Sp hing omyelinase 1 b-Galactosidase Galactocerebrosidase a-Glucosidase a-Glucosidase N -acetyltransferase Arylsulfatase A b-Hexosaminidase T b-Hexosaminidase A b -Mannosidase a-Mannosidase b-Glucuronidase Reproducibility of enzyme analysis in duplicate leukocyte samples Blind duplicate samples were analysed in 2 experiments - 10 different enzymes / sample - 2 couples of identical samples - 20 matched pairs of enzyme activities / laboratory difference between 2 activities Variation = sum of 2 activities % deviation form mean activity 100 10 20 30 40 50 60 70 80 90 0 0 1 2 3 Reproducibility, duplicateleukocytesamples 4 10% [90,110] 20% [80,120] 40% [60,140] 90% [10,190] 5 no data 6 7 8 no data 9 10 no data 11 12 Laboratory number 13 14 15 16 17 18 19 20 21 22 no data 23 24 no data 25 26 27 28 29 30 31 32 no data 33 no data 34 35 36 no data 37 % deviation form mean activity 100 10 20 30 40 50 60 70 80 90 0 0 1 2 3 Reproducibility, duplicateleukocytesamples 4 5 no data 6 no data 8labs 7 < 10% < 20% < 40% > 40% 8 no data 9 10 12 labs no data 3 labs 4 labs 11 9 labs 12 Laboratory number 13 14 15 16 17 18 19 20 21 22 no data 23 24 no data 25 26 27 28 29 30 31 32 no data 33 no data 34 35 36 no data 37 Urgently needed: QA for enzyme analysis of LSD’s Proficiency testing Lysosomal Storage Diseases 4 patient samples were included • 3 EBV lymphoblasts - Tay-Sachs (β-hexosaminidase A) - Sandhoff (β-hexosaminidase A+B) - GM1-gangliosidosis (β-galactosidase) • 1 fibroblast cell line - Gaucher type II (β-glucosidase) EBV lymphoblasts form patients % of QA-pilot controls β-Hexosaminidase A Tay 264%Sachs Sandhof GM1 EBV6 β-HexosaminidaseEBV7 A+B β-GalactosidaseEBV5 25 112% 25 25 20 20 20 15 15 15 10 10 10 % of mean QA-pilot controls 5 5 5 0 0 0 0.00 1.00 2.00 0.00 1.00 2.00 0.00 1.00 2.00 EBV lymphoblasts form patients % of QA-pilot controls β-Hexosaminidase A Tay 264%Sachs Sandhof GM1 EBV6 β-HexosaminidaseEBV7 A+B β-GalactosidaseEBV5 25 112% 25 25 20 20 20 15 15 < 13% 15 < 12% 10 10 10 % of mean QA-pilot controls 5 5 5 0 0 0 0.00 1.00 2.00 0.00 1.00 2.00 0.00 1.00 2.00 Fibroblasts from Gaucher II patient 8 12 < 11% 10 6 8 Normal β-glucosidase from QA-pilot: 4, 19, 113 – 460 nmol/h/mg (n=18) 4 6 nmol / h / mg 4 % of mean control 2 2 0 0 01234 QA for LSD’s What needs to be done • Report results to participants • Website adjustment for enzyme analysis ─ show all data, without cut-off (e.g. > 3SD) ─ show data on reproducibility of duplicate samples ─ show track records of all laboratories • More information from participants ─ which enzyme assay? [substrate, pH] ─ which homogenisation procedure? [sonication, freeze-thaw] ─ enzyme assay in: [full-homogenate, supernatant] • Increase compliance of participants ─ 10% of participants did not return any data ─ 21 - 41% of participants did not return all data QA for LSD’s Plans for 2007 / 2008 and after • Towards a new ERNDIM activity: QA-for LSD ─ Start regular ERNDIM programme in 2009 ─ Prolong the pilot phase with 2 years (2007 and 2008). - How to obtain permanent support for making the samples? - Make samples for coming QA-pilots on larger scale Leukocytes, EBV lymphoblasts, fibroblasts, DBS - Determine costs for participants for of regular ERNDIM QA-programme no cost for participants in the pilot phase (estimated participants: 50) - Start with DBS enzyme analysis, collect blood from patients - Assist to improve poor performance. • QA pilots for 2007 / 2008 Genzyme will financially support the coming 2 years. ─ February 2007 - small pilot, leukocytes, EBV lymphoblasts (fibroblasts) ─ February 2008 : - big pilot, leukocytes, EBV lymphoblasts (fibroblasts) one shipment, many samples, 4 independent experiment Enduring QA-Programme for Enzyme Analysis for Lysosomal Storage Diseases.
Load more

Recommended publications
  • Hexosaminidase in Mast Β Primary Role of Degranulation Indicator in Mast Cells?
    Does β-Hexosaminidase Function Only as a Degranulation Indicator in Mast Cells? The Primary Role of β-Hexosaminidase in Mast Cell Granules This information is current as of September 25, 2021. Nobuyuki Fukuishi, Shinya Murakami, Akane Ohno, Naoya Yamanaka, Nobuaki Matsui, Kenji Fukutsuji, Sakuo Yamada, Kouji Itoh and Masaaki Akagi J Immunol 2014; 193:1886-1894; Prepublished online 11 July 2014; Downloaded from doi: 10.4049/jimmunol.1302520 http://www.jimmunol.org/content/193/4/1886 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2014/07/11/jimmunol.130252 Material 0.DCSupplemental References This article cites 52 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/193/4/1886.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of
    [Show full text]
  • Functional Characterization of Carbohydrate-Active Enzymes from Marine Bacteria
    Functional characterization of carbohydrate-active enzymes from marine bacteria I n a u g u r a l d i s s e r t a t i o n zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Universität Greifswald vorgelegt von Marcus Bäumgen Greifswald, 28.02.2020 Dekan: Prof. Dr. Werner Weitschies 1. Gutachter: Prof. Dr. Uwe T. Bornscheuer 2. Gutachter: Prof. Dr. Harry Brumer Tag der Promotion: 24.06.2020 II III Wissenschaft ist das Werkzeug, welches es uns ermöglicht, das große Puzzel der Natur und des Lebens zu lösen. IV Auch wenn wir den Weg des Wissens und der Weisheit niemals bis zum Ende beschreiten können, so ist doch jeder Schritt, den wir tun, ein Schritt in eine bessere Welt. V Content Abbreviations ..................................................................................................................... IX 1. Introduction ..................................................................................................................... 1 1.1 The marine carbon cycle .............................................................................................. 1 1.1.1 Algal blooms .......................................................................................................... 1 1.1.2 The marine carbohydrates ulvan and xylan ........................................................... 2 1.1.3 Marine polysaccharide utilization ........................................................................... 4 1.2 Carbohydrate-active enzymes
    [Show full text]
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue
    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Pompe Disease
    Substrate Localisation as a Therapeutic Option for Pompe Disease A thesis submitted to The University of Adelaide for the degree of DOCTOR OF PHILOSOPHY by Christopher Travis Turner, BBtech (Hons) Lysosomal Diseases Research Unit Department of Genetic Medicine Women’s & Children’s Hospital North Adelaide, South Australia, 5006 October 2013 Paediatrics Paediatrics and Reproductive Health The University of Adelaide 1 Table of Contents Abstract 7 Declaration of authenticity 9 Acknowledgments 10 Abbreviations 11 List of figures 15 List of tables 18 Chapter 1 – Introduction 19 1.1 The endosome-lysosome System 20 1.1.1 The endosome 20 1.1.2 The lysosome 25 1.1.3 Autophagosomes 28 1.2 Pompe disease 36 1.2.1 Incidence 37 1.2.2 Clinical manifestations 37 1.2.3 Genetics 39 1.2.4 Diagnosis 41 1.2.5 Lysosomal acid α-glucosidase (GAA) 42 1.2.6 Glycogen synthesis and metabolism 44 1.2.6.1 Glycogen synthesis 46 1.2.6.2 Glycogen catabolism 49 2 1.2.6.3 Autophagy and lysosomal degradation of glycogen 50 1.2.7 Glycogen accumulation in Pompe disease 52 1.2.8 Treatment of Pompe disease 54 1.2.8.1 Gene therapy 54 1.2.8.2 Chaperone therapy 55 1.2.8.3 Enzyme replacement therapy 56 1.3 Exocytosis 60 1.3.1 Ca2+-dependent exocytosis 62 1.3.2 Exocytic mechanism 64 1.3.3 All-or-none exocytosis 66 1.3.4 Cavicapture 66 1.3.5 The contribution of all-or-none exocytosis and cavicapture to the overall amount of exocytosis 67 1.3.6 Evidence for the exocytosis of glycogen in Pompe disease 68 1.4 Hypothesis and aims 70 Chapter 2 – Materials and Methods 71 2.1 Materials 72
    [Show full text]
  • Glycosphingolipids Are Modulators of Disease Pathogenesis in Amyotrophic Lateral Sclerosis
    Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis James C. Dodgea,1, Christopher M. Treleavena, Joshua Pachecoa, Samantha Coopera,ChannaBaoa, Marissa Abrahama, Mandy Cromwella, S. Pablo Sardia, Wei-Lien Chuanga, Richard L. Sidmanb,1,2,SengH.Chenga, and Lamya S. Shihabuddina aRare Diseases Science, Genzyme, a Sanofi Company, Framingham, MA 01701; and bBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 Contributed by Richard L. Sidman, May 7, 2015 (sent for review January 12, 2015; reviewed by David V. Schaffer) Recent genetic evidence suggests that aberrant glycosphingolipid mediates the hydrolysis of Cer, are linked to forms of spinal metabolism plays an important role in several neuromuscular muscular atrophy that are not caused by the more frequent mu- diseases including hereditary spastic paraplegia, hereditary sen- tations in the survival motor neuron 1 gene (non-5q SMA) (15). sory neuropathy type 1, and non-5q spinal muscular atrophy. Here, Moreover, hereditary spastic paraplegia (HSP), a disease with cor- we investigated whether altered glycosphingolipid metabolism is ticospinal tract and in some cases, spinal cord MN degeneration, a modulator of disease course in amyotrophic lateral sclerosis (ALS). is attributed to mutations in GM2 synthase (16) and the non- Levels of ceramide, glucosylceramide, galactocerebroside, lactosyl- lysosomal glucosylceramidase, GBA2 (17). Last, patients with adult- ceramide, globotriaosylceramide, and the gangliosides GM3 and onset Tay-Sachs disease (GM2 gangliosidosis), a disease triggered GM1 were significantly elevated in spinal cords of ALS patients. by a deficiency in hexosaminidase (HEX), a lysosomal enzyme Moreover, enzyme activities (glucocerebrosidase-1, glucocerebrosi- that hydrolyzes GM2 to GM3, have been reported in some in- dase-2, hexosaminidase, galactosylceramidase, α-galactosidase, and stances to display a disease phenotype that closely mimics ALS β-galactosidase) mediating glycosphingolipid hydrolysis were also (18–20).
    [Show full text]
  • ZHOU-THESIS-2018.Pdf (2.307Mb)
    PHYLOGENY AND PREDICTED FUNCTIONAL CAPABILITIES OF A SULFUR- OXIDIZING AND DENITRIFYING CLADE OF BACTEROIDETES FROM SULFIDIC ENVIRONMENTS A Thesis by KECEN ZHOU Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Chair of Committee, Jason B. Sylvan Co-Chair of Committee, Lisa Campbell Committee Member, Brendan E. Roark Head of Department, Shari Yvon-Lewis August 2018 Major Subject: Oceanography Copyright 2018 Kecen Zhou ABSTRACT Environments rich in sulfur compounds (sulfidic) are common in the ocean, and the ability to gain energy (dissimilatory) from sulfur redox reactions is widespread in bacteria. The Sulfiphilic Bacteroidetes (SB), have been found exclusively in sulfidic environments, but little is known about their metabolic potential and membership. The ability to perform dissimilatory sulfur redox would make them unique among Bacteroidetes, which are primarily known as heterotrophs that specialize in degrading complex organic molecules. Using 16S rRNA phylogeny and analysis of single amplified genomes (SAGs) from Saanich Inlet, a seasonally hypoxic basin, we elucidate the global distribution and potential metabolic capabilities of the SB clade. Phylogenetic analysis revealed that this clade was monophyletic and had a global distribution. It is hypothesized this clade combines heterotrophic amino acid and sugar uptake with denitrification and respiratory sulfur oxidation/polysulfide reduction. Putative genes for sulfur oxidation via polysulfide reductase (psr) were found in the combined genome, and phylogenetic analysis confirmed these genes were likely to be psrABC. A denitrification pathway was present and complete save for the absence of a gene catalyzing reduction of NO to N2O.
    [Show full text]
  • Tay-Sachs Disease with Altered P-Hexosaminidase B: a New Variant?
    Pediat . Res. 12: 77-81 (1978) N-Acetyl P-D-hexosaminidase (Hex) heat lability Tay-Sachs disease Tay-Sachs Disease with Altered P-Hexosaminidase B: A New Variant? TORU ~0~01:~~'MASAKATSU SUDO, KENICHI TANIOKA, AND YASUJI NAKAO Department of Pediatrics, School of Medicine, Kyoto University, Kyoto, Japan SHlNlCHl HARUKl Department of Pediatrics, Himeji National Hospital, Himeji, Japan Summary its carriers, and patients with partial Hex A deficiency. Patients with partial Hex A deficiency are distinguishable from those A 2.5-year-old Japanese girl who showed signs and symptoms with ciassic TSD as the onset is later and the course milder (2, compatible with classic Tay-Sachs disease and had 'altered P- . "14, 23, 28). hexosaminidase B and I, as well as completely deficient P- We encountered a Japanese girl who showed signs and hexosaminidase A activity is reported herein. symptoms compatible with classic TSD. Hex A activities in Heat treatment of the patient's serum and leukocyte samples serum samples, as detected by the heat-inactivation method, showed the existence of 13.5-27.3% and 35.7% of the heat- revealed partial deficiency in this isozyme. As there is apparently labile component of P-hexosaminidase, respectively, such is no documentation concerning classic TSD with partial Hex A usually considered to correspond to /3-hexosaminidase A. The deficiency, we investigated the nature of the heat lability of absence of Phexosaminidase A activity was confirmed by Hex in our patient and the findings are reported herein. DEAE-cellulose column chromatography and cellulose acetate paper electrophoresis. The patient's serum P-hexosaminidase also contained a significant amount of acid pH-labile compo- CASE REPORT nents.
    [Show full text]
  • New Approaches to Correcting Metabolic Errors in Tay-Sachs
    New Approaches to Correcting Metabolic Errors in Tay-Sachs New Approaches to Correcting Metabolic Errors in Tay-Sachs Katherine Stefanski Abstract Tay-Sachs Disease (TSD) is a neurodegenerative disorder categorized as both a gangliosidosis and a lysosomal storage disease. Tay-Sachs is caused by a deficiency in the enzymeβ -hexosaminidase A (Hex A). There is no current remedy available for TSD. However, there have been promising studies and breakthroughs on the use of gene therapy to cure Tay-Sachs, and these studies will be discussed in this review article. Initial progress was made using a cell line model for TSD which led to subsequent studies in HEXA null knock-out mice and mice with Sandhoff disease (a related disease involving the same enzyme). Eventually, researchers were able to transduce the brain of Sandhoff mice correcting the diseases neurological symptoms. Most recently, felines with Sandhoff disease were also successfully treated with gene therapy. Advances made in lifespan, quality of life, and relative safety of the treatment in animal models implies a readiness for human trials. Middle Tennessee State University 43 Scientia et Humanitas: A Journal of Student Research Introduction Background ay-Sachs disease (TSD), named for the two physicians who first described it, was discovered by Warren Tay, a British ophthalmologist, and Bernard Sachs, a neurologistT from New York City. The disease presents beginning around six months of age with early blindness, severe mental retardation, paralysis, and in most cases death early in childhood before four years of age. It is most commonly seen in children of Eastern Eu- ropean Ashkenazi Jewish descent as well as some French Canadian and Louisiana Cajun populations.1 TSD is an autosomal recessive disorder caused by a mutation in the gene that encodes for the lysosomal enzyme β-hexosaminidase A (Hex A), HEXA.2 Metabolic Basis of Tay-Sachs TSD is classified as both a gangliosidosis and a lysosomal storage disease.2,3 Ganglio- sides are the principal glycolipid comprising neuronal plasma membranes.
    [Show full text]
  • Impaired Β-Glucocerebrosidase Activity and Processing in Frontotemporal Dementia Due to Progranulin Mutations Andrew E
    Arrant et al. Acta Neuropathologica Communications (2019) 7:218 https://doi.org/10.1186/s40478-019-0872-6 RESEARCH Open Access Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations Andrew E. Arrant1,2*, Jonathan R. Roth1, Nicholas R. Boyle1, Shreya N. Kashyap1, Madelyn Q. Hoffmann1, Charles F. Murchison1,3, Eliana Marisa Ramos4, Alissa L. Nana5, Salvatore Spina5, Lea T. Grinberg5,6, Bruce L. Miller5, William W. Seeley5,6 and Erik D. Roberson1,7* Abstract Loss-of-function mutations in progranulin (GRN) are a major autosomal dominant cause of frontotemporal dementia. Most pathogenic GRN mutations result in progranulin haploinsufficiency, which is thought to cause frontotemporal dementia in GRN mutation carriers. Progranulin haploinsufficiency may drive frontotemporal dementia pathogenesis by disrupting lysosomal function, as patients with GRN mutations on both alleles develop the lysosomal storage disorder neuronal ceroid lipofuscinosis, and frontotemporal dementia patients with GRN mutations (FTD-GRN) also accumulate lipofuscin. The specific lysosomal deficits caused by progranulin insufficiency remain unclear, but emerging data indicate that progranulin insufficiency may impair lysosomal sphingolipid- metabolizing enzymes. We investigated the effects of progranulin insufficiency on sphingolipid-metabolizing enzymes in the inferior frontal gyrus of FTD-GRN patients using fluorogenic activity assays, biochemical profiling of enzyme levels and posttranslational modifications, and quantitative neuropathology. Of the enzymes studied, only β-glucocerebrosidase exhibited impairment in FTD-GRN patients. Brains from FTD-GRN patients had lower activity than controls, which was associated with lower levels of mature β-glucocerebrosidase protein and accumulation of insoluble, incompletely glycosylated β-glucocerebrosidase. Immunostaining revealed loss of neuronal β- glucocerebrosidase in FTD-GRN patients.
    [Show full text]
  • Mutagenesis of Human Alpha-Galactosidase a for the Treatment of Fabry Disease
    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 9-2017 Mutagenesis of Human Alpha-Galactosidase A for the Treatment of Fabry Disease Erin Stokes The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/2338 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] CITY COLLEGE, CITY UNIVERSITY OF NEW YORK MUTAGENESIS OF HUMAN ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE By Erin Stokes A dissertation submitted to the Graduate Faculty in Biochemistry in partial fulfillment of the requirement for the degree of Doctor of Philosophy, The City University of New York 2017 ©2017 Erin Stokes All rights reserved ii Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease By Erin Stokes This manuscript has been read and accepted for the Graduate Faculty Biochemistry in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ______________________ David H. Calhoun Date Chair of Examining Committee ______________________ Richard Magliozzo Date Executive Officer Supervisory Committee: Haiping Cheng (Lehman College, CUNY) M. Lane Gilchrist (City College of New York, CUNY) Emanuel Goldman (New Jersey Medical School, Rutgers) Kevin Ryan (City College of New York, CUNY) THE CITY UNIVERSITY OF NEW YORK iii Abstract Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease By Erin Stokes Advisor: Dr.
    [Show full text]
  • Carrier Detection for Tay-Sachs Disease: a Model for Genetic Disease Prevention
    Carrier detection for Tay-Sachs disease: a model for genetic disease prevention Irene De Biase, MD PhD Assistant Professor of Pathology, University of Utah Assistant Medical Director, Biochemical Genetics and Supplemental Newborn Screening, ARUP Laboratories Conflict of Interest . None to declare Learning objectives . Review the clinical characteristics and the biochemical features of Tay-Sachs Disease . Describe the population-based screening for Tay-Sachs disease and its impact on disease incidence . Explore the unique challenges in carrier testing for Tay-Sachs disease Cherry red spot Warren Tay British ophthalmologist In 1881, he described the cherry red spot on the retina of a one-year old child with mental and physical retardation NOVEL collection University of Utah Bernard Sachs Jewish-American neurologist In 1896, observed the extreme swelling of neurons in autopsy tissue of affected children Also noticed the disease seemed to be of Jewish origin TSD is a lysosomal storage disease . The underlying biochemical defect is the profound deficiency of the lysosomal hydrolase b-hexosaminidase A . HexA is necessary for the break-down of the ganglioside GM2, a component of the plasma membrane Okada et al. Science 1969; 165:698-700 Degradation of glycosphingolipids GM2 Generalized Gangliosidosis GA2 Sandhoff Disease Tay-Sachs Disease Fabry Disease Metachromatic leukodystrophy Gaucher Disease Krabbe Disease Essentials of Glycobiology Second Edition b-hexosaminidase isoforms: HexA and HexB GM2 Generalized Gangliosidosis GA2 Tay-Sachs Disease HexB: ββ Sandhoff Disease GM2 HexA: αβ activator Fabry Disease GM2 activator Metachromatic leukodystrophy Gaucher Disease Krabbe Disease Essentials of Glycobiology Second Edition Three gene system required for HexA activity 1. 2.
    [Show full text]